{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:46:18Z","timestamp":1791225978340,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.vaccine.2011.03.090","type":"journal-article","created":{"date-parts":[[2011,4,19]],"date-time":"2011-04-19T04:46:13Z","timestamp":1303188373000},"page":"3951-3961","source":"Crossref","is-referenced-by-count":47,"title":["A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus"],"prefix":"10.1016","volume":"29","author":[{"given":"Dubravka Grdic","family":"Eliasson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Helgeby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Sch\u00f6n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Nygren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"El-Bakkouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Fiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Saelens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin Bengtsson","family":"L\u00f6vgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Nystr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils Y.","family":"Lycke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"August (1163)","key":"10.1016\/j.vaccine.2011.03.090_bib0005","first-page":"65","article-title":"FluMist: an intranasal live influenza vaccine","volume":"45","author":"Abramowicz","year":"2003","journal-title":"Med Lett Drugs Ther"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2011.03.090_bib0010","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/ni0504-460","article-title":"Vaccine development strategies for improving immunization: the role of modern immunology","volume":"5","author":"Levine","year":"2004","journal-title":"Nat Immunol"},{"issue":"November (Suppl. 2)","key":"10.1016\/j.vaccine.2011.03.090_bib0015","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1086\/507544","article-title":"Vaccines for seasonal and pandemic influenza","volume":"194","author":"Nichol","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.03.090_bib0020","series-title":"Immunity against mucosal pathogens","author":"Vajdy","year":"2008"},{"issue":"February (1)","key":"10.1016\/j.vaccine.2011.03.090_bib0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.coi.2009.01.004","article-title":"Mechanism of action of clinically approved adjuvants","volume":"21","author":"Lambrecht","year":"2009","journal-title":"Curr Opin Immunol"},{"issue":"September\u2013October (5)","key":"10.1016\/j.vaccine.2011.03.090_bib0030","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4161\/hv.4.5.6438","article-title":"Vaccine adjuvants: the dream becomes real","volume":"4","author":"Tagliabue","year":"2008","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2011.03.090_bib0035","series-title":"Vaccine adjuvants and delivery systems","first-page":"53","article-title":"Mechanisms of adjuvant action","author":"Lycke","year":"2007"},{"issue":"April (13)","key":"10.1016\/j.vaccine.2011.03.090_bib0040","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1021\/bi0360152","article-title":"Crystal structures of an intrinsically active cholera toxin mutant yield insight into the toxin activation mechanism","volume":"43","author":"O\u2019Neal","year":"2004","journal-title":"Biochemistry"},{"issue":"9","key":"10.1016\/j.vaccine.2011.03.090_bib0045","doi-asserted-by":"crossref","first-page":"e6999","DOI":"10.1371\/journal.pone.0006999","article-title":"Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin","volume":"4","author":"Lewis","year":"2009","journal-title":"PLoS One"},{"issue":"Febuary (9)","key":"10.1016\/j.vaccine.2011.03.090_bib0050","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa030595","article-title":"Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland","volume":"350","author":"Mutsch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2011.03.090_bib0055","series-title":"New generation vaccines","first-page":"273","article-title":"Use of genetically or chemically detoxified mutants of Cholera and Escherichia coli heat-labile enterotoxins as mucosal adjuvants","author":"Freytag","year":"2010"},{"issue":"April (8)","key":"10.1016\/j.vaccine.2011.03.090_bib0060","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.4049\/jimmunol.158.8.3936","article-title":"Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit","volume":"158","author":"Agren","year":"1997","journal-title":"J Immunol"},{"issue":"July (1)","key":"10.1016\/j.vaccine.2011.03.090_bib0065","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jri.2009.04.002","article-title":"CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa","volume":"81","author":"Cunningham","year":"2009","journal-title":"J Reprod Immunol"},{"issue":"February (9)","key":"10.1016\/j.vaccine.2011.03.090_bib0070","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.vaccine.2007.12.027","article-title":"CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine","volume":"26","author":"Eliasson","year":"2008","journal-title":"Vaccine"},{"issue":"December","key":"10.1016\/j.vaccine.2011.03.090_bib0075","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1099\/vir.0.2008\/005470-0","article-title":"CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization","volume":"89(Pt 12)","author":"Sundling","year":"2008","journal-title":"J Gen Virol"},{"issue":"September (5)","key":"10.1016\/j.vaccine.2011.03.090_bib0080","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.4049\/jimmunol.173.5.3310","article-title":"The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues","volume":"173","author":"Eriksson","year":"2004","journal-title":"J Immunol"},{"issue":"September (6)","key":"10.1016\/j.vaccine.2011.03.090_bib0085","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.4049\/jimmunol.167.6.3398","article-title":"CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen","volume":"167","author":"Mowat","year":"2001","journal-title":"J Immunol"},{"issue":"March\u2013April (5958)","key":"10.1016\/j.vaccine.2011.03.090_bib0090","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/308457a0","article-title":"Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses","volume":"308","author":"Morein","year":"1984","journal-title":"Nature"},{"issue":"April (2)","key":"10.1016\/j.vaccine.2011.03.090_bib0095","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1470-8744.1988.tb00012.x","article-title":"The requirement of lipids for the formation of immunostimulating complexes (iscoms)","volume":"10","author":"Lovgren","year":"1988","journal-title":"Biotechnol Appl Biochem"},{"issue":"June (25)","key":"10.1016\/j.vaccine.2011.03.090_bib0100","doi-asserted-by":"crossref","first-page":"9363","DOI":"10.1073\/pnas.0403271101","article-title":"Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant","volume":"101","author":"Chen","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"February (9\u201310)","key":"10.1016\/j.vaccine.2011.03.090_bib0105","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0264-410X(02)00545-5","article-title":"Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine","volume":"21","author":"Coulter","year":"2003","journal-title":"Vaccine"},{"issue":"September (40)","key":"10.1016\/j.vaccine.2011.03.090_bib0110","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1016\/j.vaccine.2009.06.085","article-title":"The first safe inactivated equine influenza vaccine formulation adjuvanted with ISCOM-Matrix that closes the immunity gap","volume":"27","author":"Heldens","year":"2009","journal-title":"Vaccine"},{"issue":"September (1\u20133)","key":"10.1016\/j.vaccine.2011.03.090_bib0115","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0169-409X(01)00165-X","article-title":"Immunostimulating complexes (ISCOMs) for nasal vaccination","volume":"51","author":"Hu","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"issue":"July (9)","key":"10.1016\/j.vaccine.2011.03.090_bib0120","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/0264-410X(94)90297-6","article-title":"Antigenicity and immunogenicity of experimental equine influenza ISCOM vaccines","volume":"12","author":"Mumford","year":"1994","journal-title":"Vaccine"},{"issue":"October (1\u20132)","key":"10.1016\/j.vaccine.2011.03.090_bib0125","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0264-410X(01)00262-6","article-title":"A single dose of an ISCOM influenza vaccine induces long-lasting protective immunity against homologous challenge infection but fails to protect Cynomolgus macaques against distant drift variants of influenza A (H3N2) viruses","volume":"20","author":"Rimmelzwaan","year":"2001","journal-title":"Vaccine"},{"issue":"September (27\u201328)","key":"10.1016\/j.vaccine.2011.03.090_bib0130","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1016\/j.vaccine.2004.03.026","article-title":"ISCOMATRIX adjuvant: an adjuvant suitable for use in anticancer vaccines","volume":"22","author":"Stewart","year":"2004","journal-title":"Vaccine"},{"issue":"July (33)","key":"10.1016\/j.vaccine.2011.03.090_bib0135","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1016\/j.vaccine.2009.05.032","article-title":"ISCOMs and ISCOMATRIX","volume":"27","author":"Sun","year":"2009","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2011.03.090_bib0140","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/BF01240612","article-title":"Saponin adjuvants. 3. Isolation of a substance from Quillaja saponaria Molina with adjuvant activity in food-and-mouth disease vaccines","volume":"44","author":"Dalsgaard","year":"1974","journal-title":"Arch Gesamte Virusforsch"},{"key":"10.1016\/j.vaccine.2011.03.090_bib0145","series-title":"Vaccine adjuvants and delivery systems","first-page":"191","article-title":"New ISCOMs meet unsettled vaccine demands","author":"Morein","year":"2007"},{"issue":"September (9)","key":"10.1016\/j.vaccine.2011.03.090_bib0150","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.bbagen.2006.05.004","article-title":"Structure-activity relationships of some hederagenin diglycosides: haemolysis, cytotoxicity and apoptosis induction","volume":"1760","author":"Chwalek","year":"2006","journal-title":"Biochim Biophys Acta"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2011.03.090_bib0155","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s00262-004-0598-5","article-title":"Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer","volume":"54","author":"Slovin","year":"2005","journal-title":"Cancer Immunol Immunother"},{"issue":"March (6)","key":"10.1016\/j.vaccine.2011.03.090_bib0160","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.4049\/jimmunol.176.6.3697","article-title":"The combined CTA1-DD\/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells","volume":"176","author":"Helgeby","year":"2006","journal-title":"J Immunol"},{"issue":"April (5772)","key":"10.1016\/j.vaccine.2011.03.090_bib0165","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1126\/science.312.5772.380","article-title":"A one-size-fits-all flu vaccine?","volume":"312","author":"Kaiser","year":"2006","journal-title":"Science"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2011.03.090_bib0170","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/13484","article-title":"A universal influenza A vaccine based on the extracellular domain of the M2 protein","volume":"5","author":"Neirynck","year":"1999","journal-title":"Nat Med"},{"issue":"15","key":"10.1016\/j.vaccine.2011.03.090_bib0175","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/0264-410X(95)92777-Y","article-title":"Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein","volume":"13","author":"Slepushkin","year":"1995","journal-title":"Vaccine"},{"issue":"May (10)","key":"10.1016\/j.vaccine.2011.03.090_bib0180","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.4049\/jimmunol.156.10.3892","article-title":"Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein","volume":"156","author":"Tamura","year":"1996","journal-title":"J Immunol"},{"issue":"June (11)","key":"10.1016\/j.vaccine.2011.03.090_bib0185","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1128\/JVI.75.11.5141-5150.2001","article-title":"Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection","volume":"75","author":"Tumpey","year":"2001","journal-title":"J Virol"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2011.03.090_bib0190","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/protein\/12.2.173","article-title":"Hydrophobicity engineering of cholera toxin A1 subunit in the strong adjuvant fusion protein CTA1-DD","volume":"12","author":"Agren","year":"1999","journal-title":"Protein Eng"},{"issue":"December (4)","key":"10.1016\/j.vaccine.2011.03.090_bib0195","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1128\/MMBR.56.4.622-647.1992","article-title":"Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin","volume":"56","author":"Spangler","year":"1992","journal-title":"Microbiol Rev"},{"issue":"October (2)","key":"10.1016\/j.vaccine.2011.03.090_bib0200","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0014-5793(91)81311-U","article-title":"Glutamic acid-112 of the A subunit of heat-labile enterotoxin from enterotoxigenic Escherichia coli is important for ADP-ribosyltransferase activity","volume":"291","author":"Tsuji","year":"1991","journal-title":"FEBS Lett"},{"issue":"December (3)","key":"10.1016\/j.vaccine.2011.03.090_bib0205","first-page":"435","article-title":"An experimental influenza subunit vaccine (iscom): induction of protective immunity to challenge infection in mice after intranasal or subcutaneous administration","volume":"82","author":"Lovgren","year":"1990","journal-title":"Clin Exp Immunol"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2011.03.090_bib0210","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.it.2008.09.006","article-title":"New horizons in adjuvants for vaccine development","volume":"30","author":"Reed","year":"2009","journal-title":"Trends Immunol"},{"issue":"August (36)","key":"10.1016\/j.vaccine.2011.03.090_bib0215","doi-asserted-by":"crossref","first-page":"5817","DOI":"10.1016\/j.vaccine.2010.06.069","article-title":"Genetic control of immune responses to influenza A matrix 2 protein (M2)","volume":"28","author":"Misplon","year":"2010","journal-title":"Vaccine"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2011.03.090_bib0220","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3201\/eid1204.051020","article-title":"Prospects for universal influenza virus vaccine","volume":"12","author":"Gerhard","year":"2006","journal-title":"Emerg Infect Dis"},{"issue":"June (1)","key":"10.1016\/j.vaccine.2011.03.090_bib0225","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.virol.2005.04.004","article-title":"Universal influenza A vaccine: optimization of M2-based constructs","volume":"337","author":"De Filette","year":"2005","journal-title":"Virology"},{"issue":"October (45)","key":"10.1016\/j.vaccine.2011.03.090_bib0230","doi-asserted-by":"crossref","first-page":"6280","DOI":"10.1016\/j.vaccine.2009.07.007","article-title":"M2e-based universal influenza A vaccine","volume":"27","author":"Fiers","year":"2009","journal-title":"Vaccine"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2011.03.090_bib0235","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/erv.09.6","article-title":"Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments","volume":"8","author":"Schotsaert","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"August (3)","key":"10.1016\/j.vaccine.2011.03.090_bib0240","first-page":"213","article-title":"Comparison of adverse reactions to whole-virion and split-virion influenza vaccines in hospital personnel","volume":"145","author":"al-Mazrou","year":"1991","journal-title":"CMAJ"},{"issue":"April (17)","key":"10.1016\/j.vaccine.2011.03.090_bib0245","doi-asserted-by":"crossref","first-page":"11382","DOI":"10.1074\/jbc.M800650200","article-title":"An influenza A vaccine based on tetrameric ectodomain of matrix protein 2","volume":"283","author":"De Filette","year":"2008","journal-title":"J Biol Chem"},{"issue":"May (10)","key":"10.1016\/j.vaccine.2011.03.090_bib0250","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.1128\/JVI.79.10.5943-5951.2005","article-title":"Roles of CD4+ T-cell-independent and -dependent antibody responses in the control of influenza virus infection: evidence for noncognate CD4+ T-cell activities that enhance the therapeutic activity of antiviral antibodies","volume":"79","author":"Mozdzanowska","year":"2005","journal-title":"J Virol"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2011.03.090_bib0255","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3201\/eid1303.061125","article-title":"Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1","volume":"13","author":"Tompkins","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2011.03.090_bib0260","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1743-422X-4-118","article-title":"Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse","volume":"4","author":"Mozdzanowska","year":"2007","journal-title":"Virol J"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2011.03.090_bib0265","first-page":"317","article-title":"Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route","volume":"72","author":"Mowat","year":"1991","journal-title":"Immunology"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2011.03.090_bib0270","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/intimm\/dxg067","article-title":"A role for dendritic cells in the priming of antigen-specific CD4+ and CD8+ T lymphocytes by immune-stimulating complexes in vivo","volume":"15","author":"Beacock-Sharp","year":"2003","journal-title":"Int Immunol"},{"issue":"September (1)","key":"10.1016\/j.vaccine.2011.03.090_bib0275","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1046\/j.1365-2567.2003.01705.x","article-title":"The role of antigen-presenting cells and interleukin-12 in the priming of antigen-specific CD4+ T cells by immune stimulating complexes","volume":"110","author":"Robson","year":"2003","journal-title":"Immunology"},{"issue":"October (3)","key":"10.1016\/j.vaccine.2011.03.090_bib0280","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1083\/jcb.151.3.673","article-title":"The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments","volume":"151","author":"Mahnke","year":"2000","journal-title":"J Cell Biol"},{"issue":"July (27)","key":"10.1016\/j.vaccine.2011.03.090_bib0285","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1016\/S0264-410X(00)00118-3","article-title":"Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity","volume":"18","author":"Marciani","year":"2000","journal-title":"Vaccine"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2011.03.090_bib0290","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/eji.200737758","article-title":"Simultaneous presentation and cross-presentation of immune-stimulating complex-associated cognate antigen by antigen-specific B cells","volume":"38","author":"Robson","year":"2008","journal-title":"Eur J Immunol"},{"issue":"February (3)","key":"10.1016\/j.vaccine.2011.03.090_bib0295","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.4049\/jimmunol.172.3.1501","article-title":"CpG-DNA aided cross-priming by cross-presenting B cells","volume":"172","author":"Heit","year":"2004","journal-title":"J Immunol"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2011.03.090_bib0300","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/89775","article-title":"IgA production without mu or delta chain expression in developing B cells","volume":"2","author":"Macpherson","year":"2001","journal-title":"Nat Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1100483X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1100483X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T07:03:17Z","timestamp":1686034997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1100483X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":60,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0264410X1100483X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.03.090","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}